Cobra Venom Factor 眼镜蛇毒液因子

 Naja naja kaouthia

 > 95% by SDS-Page

 Approximately 1.0 mg/mL

 Phosphate Buffered Saline (pH 7.2 ± 0.2)

  ≤ 70°C

 Cobra Venom Factor (CVF), sometimes referred to as C3b (Cobra), is the non-toxic, complement-activating component of cobra venom. Like naturally occurring human C3b, CVF forms a complex, or convertase, with complement components Factor B and Factor D. This CVFBbD convertase is capable of activating C3 in a wide variety of species via the alternative complement pathway. CVFBbD convertase is Factor H resistant and is therefore not blocked through the activity of Factor I or CR1 and can convert nearly 100% of the C3 to C3 and C5 fragments. Levels of iC3b, C3a, SC5b-9, C5a and the Factor B cleavage product Bb are all extremely high in CVF treated sera.

This product has been used in an experimental setting to deplete complement activity in vitro and in vivo. For more information contact Quidel Technical Support.

 Purified CVF may be stored at –70°C until the expiration date listed on the vial and the accompanying Certificate of Analysis. CVF should be thawed rapidly at 37°C and immediately placed on ice until use

 When using any CVF in vivo or in vitro, it is important to monitor units of activity rather than μg/ml as activity/μg can vary slightly between preparations and suppliers. In general, one unit of CVF is equal to 2 μg to 6 μg of CVF.

 Agarwal, Szalai, A. The Arthus Reaction in Rodents: Species Specific Requirement of Complement, J. Immunol 164:463-468, 2000.

Vandenberg, C.W., et al. In Vivo Anti-complementary activities of the cobra venom factros form Naja and Naja haje, J. Immunol. Methods. 13(6):2870294, 1991.

Rajasinghe, H. et al. Key role of the alternative pathway in hyperacute rejection of rat hearts transplanted into fetal sheep, Transplantation. 63(3), 407-426, 1996.

Koymada, N. Bach, F. Transient complement inhibition plus T Cell immuno-suppression induces long term survival of mouse to rat cardiac xenografts, Transplantation. 6(9)1210-1215, 1998.